Although recent studies propose uPAR as a good candidate for antibody-targeted therapy in cancer [51,52,53,54,55], our results show that these treatments could, at the same time, induce cellular dormancy and render the tumor more resistant to chemotherapy (such as gemcitabine). Here, PLAUR is linked to neoplasm.